Effective anti-infective
therapies are required to offset the rise
in antibiotic resistance. A novel vancomycin-innate defense regulator
conjugate (V–IDR1018) was constructed with multimodal functionality,
including bacterial killing, biofilm eradication, and immune modulation.
The conjugate killed bacteria within 30 min, exhibited potent activity
against persister cells, and showed no susceptibility to antimicrobial
resistance in tissue culture assays. Additionally, it stimulated the
release of chemokine MCP-1 and anti-inflammatory cytokine IL-10 and
suppressed pro-inflammatory IL-1β from lipopolysaccharide-stimulated
white blood cells. The conjugate demonstrated ∼90% eradication
efficacy when assessed against the MRSA biofilm formed on an organoid
human skin equivalent. Similarly, when evaluated in a murine, high-density
skin abscess infection model using MRSA or Staphylococcus
epidermidis, the conjugate decreased dermonecrosis
and reduced bacterial load. The exceptional in vitro and in vivo efficacy of the conjugate, in addition
to its safety profile, makes it a valuable candidate to treat complex
infectious diseases.